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Abstract
Mechanistic studies of O-GlcNAc glycosylation have been limited by an inability to monitor the
glycosylation stoichiometries of proteins obtained from cells. Here, we describe a powerful
method to visualize the O-GlcNAc-modified protein subpopulation using resolvable polyethylene
glycol mass tags. This approach enables rapid quantification of in vivo glycosylation levels on
endogenous proteins without the need for protein purification, advanced instrumentation, or
expensive radiolabels. In addition, the glycosylation state (e.g., mono-, di-, tri-) of proteins is
established, providing information regarding overall O-GlcNAc site occupancy that cannot be
obtained using mass spectrometry. Finally, we apply this strategy to rapidly assess the complex
interplay between glycosylation and phosphorylation, and discover an unexpected reverse yin-
yang relationship on the transcriptional repressor MeCP2, which was undetectable by traditional
methods. We anticipate that this mass-tagging strategy will advance our understanding of O-
GlcNAc glycosylation, as well as other post-translational modifications and poorly understood
glycosylation motifs.
Protein post-translational modifications represent an important molecular mechanism for the
control of complex biological systems. One example is O-GlcNAc glycosylation, the
dynamic addition of N-acetyl-D-glucosamine to serine or threonine residues of intracellular
proteins1–3. O-GlcNAc plays key roles in diverse processes such as glucose homeostasis1,4,
cardiac muscle survival5, cell cycle progression6, and synaptic transmission7. However, like
many post-translational modifications, O-GlcNAc glycosylation has intrinsic characteristics
(e.g., labile, present in low cellular abundance, ubiquitous), which have hindered both its
detection and mechanistic studies2.
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Hundreds of O-GlcNAc-modified proteins have been identified by mass spectrometry8–10,
yet in vivo glycosylation levels are known for only a few11–15, and there are currently no
methods to assess whether proteins exist in singly, doubly or multiply glycosylated states in
vivo. Knowledge of glycosylation stoichiometries is essential for understanding the function
and regulation of O-GlcNAc. Moreover, the ability to quantify O-GlcNAc stoichiometries
should help overcome a major bottleneck in the field – namely, the prioritization of proteins
in the O-GlcNAc proteome for in-depth characterization and functional analysis.
Current methods to assess glycosylation stoichiometries are time-consuming and require
large amounts of purified protein. GlcNAc levels are typically quantified by radioactivity or
high pH anion exchange chromatography-pulsed amperometric detection (HPAEC-PAD)11–
15
. However, there are no general methods for measuring O-GlcNAc glycosylation levels on
unpurified, endogenous proteins. Furthermore, monitoring the dynamics of O-GlcNAc
glycosylation on specific proteins is challenging because O-GlcNAc site-specific antibodies
are notoriously difficult to generate16. As such, rapid, parallel, and low-cost methods are
needed to study O-GlcNAc glycosylation stoichiometries and to understand their dynamic
regulation across different tissues and (patho)physiological states.
In addition to quantifying stoichiometries, a related challenge is to understand the interplay
between different post-translational modifications. For instance, there is an intriguing
potential for O-GlcNAc and phosphorylation to act reciprocally or engage in combinatorial
crosstalk at the level of signaling cascades1,7,17–20. To establish ‘yin-yang’ reciprocity, the
addition of a phosphate group must affect the glycosylation state of the same molecule and
vice versa. However, until now, there have been no general methods to study the kinetics of
glycosylation on only the phosphorylated protein subpopulation or vice versa.
We describe a novel strategy that overcomes these challenges, unraveling the stoichiometry
and dynamics of O-GlcNAc glycosylation in vivo and revealing new insights into the
intricate interplay between glycosylation and phosphorylation. Using this strategy, we show
that O-GlcNAc stoichiometries occur over a wide range in vivo and are subject to tight
regulatory control. In addition, we identify a complex, reverse yin-yang relationship on the
transcriptional repressor MeCP2 that would be missed using traditional approaches.
RESULTS
Mass-tagging strategy to quantify O-GlcNAc stoichiometry
We reasoned that the selective attachment of a defined molecular mass tag to terminal
GlcNAc sugars would enable rapid visualization of O-GlcNAc glycosylated proteins of
interest (Fig. 1a). Specifically, O-GlcNAc-modified proteins from cell lysates could be
labeled with the mass tag, resolved by SDS-PAGE, and visualized in parallel by
immunoblotting with antibodies against proteins of interest. Simple inspection of the mass-
shifted bands would establish whether a protein was mono-, di- or multiply glycosylated,
and in vivo glycosylation stoichiometries could be determined by quantifying the relative
intensities of each band. We chose polyethylene glycol (PEG) for the mass tag because it is
aqueous-soluble, highly flexible, chemically inert, and available in various well-defined
molecular weight ranges. Although PEG has been used extensively to modulate the
pharmacokinetics and other properties of proteins21, it has not been exploited as a tool to
advance an understanding of post-translational modifications. Aminooxy-functionalized 2
and 3 were readily synthesized in one chemical step from commercially available PEG 2K
and 5K derivatives, respectively (Supplementary Scheme 1 and Supplementary Figs. 1–4).
To attach the mass tag onto O-GlcNAc proteins, we used our previously reported
chemoenzymatic labeling strategy8,9,22. This approach allows for selective and complete
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labeling of terminal GlcNAc sugars using an engineered β-1,4-galactosyltransferase22,23
(Y289L GalT). Structural and mechanistic studies have shown that GalT selectively labels
terminal GlcNAc sugars23,24 without regard for the surrounding peptide sequence23,
indicating that it should not discriminate between specific glycosylation sites. Moreover, the
GalT labeling method has been the gold standard for quantitative radiolabeling of purified
O-GlcNAc glycosylated proteins in vitro12.
We first investigated the approach on two preparations of purified cAMP-response element
binding protein (CREB), which differed only in their extent of glycosylation25. CREB
expressed alone in Sf9 cells (CREBmono) and CREB co-expressed with O-GlcNAc
transferase (OGT; CREBco) were incubated with the Y289L GalT and UDP-ketogalactose
analogue 122, after which the transferred ketone moiety was reacted with the aminooxy-
functionalized PEG derivative 2 or 3 (Fig. 1a). The labeled proteins were resolved by SDS-
PAGE and analyzed by Western blotting using an anti-CREB antibody. Reaction of
CREBmono with 2 or 3 produced an expected shift of molecular mass (2 kDa or 5 kDa,
respectively) consistent with labeling of a single GlcNAc moiety (Fig. 1b). Omission of the
UDP-ketone substrate 1 prevented the mass shift and confirmed the specificity of the
reaction. By measuring the relative intensities of the glycosylated and nonglycosylated
protein bands, the stoichiometry of glycosylation of CREBmono was calculated to be 28.2%
(24.1% monoglycosylated, 4.1% diglycosylated). As expected, CREBco exhibited a higher
extent of glycosylation (88.8%) as well as the presence of multiple mass-shifted bands.
Inspection of the blot revealed four 2 kDa- or 5 kDa-incremental shifts in molecular mass,
indicating that CREBco contains at least four glycosylation sites and exists as a mixture of
mono-, di-, tri- and tetraglycosylated forms (31.8% monoglycosylated, 29.2%
diglycosylated, 18.2% triglycosylated and 9.6% tetraglycosylated). Accounting for the
number of O-GlcNAc units in each glycoform (e.g., 1 for the monoglycosylated form, 2 for
the diglycosylated form, etc.) and the percentage of each glycoform, we calculated a ratio of
183:32 GlcNAc groups for CREBco:CREBmono. This corresponds to a 5.7-fold increase in
glycosylation, similar to that obtained previously by radiolabeling25.
Approach Validation
For accurate quantification of O-GlcNAc stoichiometries, the following criteria must be
satisfied: 1) the enzymatic labeling and PEGylation reaction must proceed to completion, 2)
the PEG tag must not interfere significantly with Western blotting, and 3) detection of the
labeled glycoprotein must be linear across a wide range of stoichiometries. Completion of
both the enzymatic labeling and oxime formation steps has been demonstrated by mass
spectrometry of O-GlcNAc-modified peptides22. As further verification, we incubated PEG-
labeled CREBmono with an aminooxybiotin derivative to cap any unreacted ketone groups.
No biotin incorporation was detected by streptavidin-IR800, whereas the CREBmono control
lacking 3 gave a strong streptavidin signal (Supplementary Fig. 5). Furthermore, we tested
the labeling of two proteins known to be highly glycosylated, Nup62 and Sp113,26,27. Rat
brain or 293T cell lysates were labeled using an optimized procedure and immunoblotted for
Nup62 or Sp1, respectively. Importantly, we detected complete labeling of both proteins and
the addition of 10 PEG units to Nup62, consistent with labeling of the 10 reported Nup62
sites27 (Fig. 1c).
To confirm that the PEG tag does not interfere significantly with immunoblotting, we
compared several antibodies. The anti-OGT antibodies AL-28 and DM-17 detected the same
extent of glycosylation on OGT (Fig. 2a). Similarly, no differences in the stoichiometries of
CREB or the transcriptional repressor MeCP2 were calculated using two distinct antibodies
against each protein. Given the low stoichiometry of OGT glycosylation (3.3%), we used
OGT to test the detection sensitivity of the mass-tagging method. We measured the
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glycosylation stoichiometries of six OGT standards, which were generated by serial dilution
of labeled and unlabeled lysates (Fig. 2b). As little as 0.8% of glycosylated OGT could be
readily detected, highlighting the sensitivity of the approach.
Lastly, we confirmed that PEGylation of O-GlcNAc glycosylated proteins was linearly
related to the glycosylation stoichiometry, particularly at high stoichiometries where a large
number of PEG molecules might preclude linear detection. A standard curve was generated
to simulate a wide range of glycosylation (0–100%) by treating lysates containing varying
concentrations of ketogalactose-labeled proteins with 2 (Fig. 2c). Importantly, the intensity
of the mass-shifted bands (i.e. the extent of label incorporation) was linearly proportional to
the extent of Nup62 glycosylation over the entire stoichiometry range.
Profiling in vivo glycosylation stoichiometries
An important implication of the approach is that labeling O-GlcNAc proteins with
resolvable mass tags should enable the first comprehensive profiling of in vivo glycosylation
levels. To investigate the generality of the approach, we compared the glycosylation levels
of a diverse set of proteins from different biological samples. We found that there exists a
broad range of in vivo O-GlcNAc stoichiometries, even among proteins with similar
functions (Fig. 1c). Whereas synapsin IIa was glycosylated at a very low level (2.3%) in the
adult rat brain cortex, the entire population of Nup62 was modified in the same tissue
sample. The transcription factor Sp1 was highly glycosylated at multiple sites in accordance
with previous reports13, while a smaller (33.0%) subpopulation of CREB was singly
modified in embryonic cortical neurons. MeCP2, a transcriptional repressor whose loss
underlies mental retardation in Rett’s Syndrome, was 15.3% mono-glycosylated in the rat
hypothalamus, a small brain structure where MeCP2 regulates stress and metabolism28.
Interestingly, low glycosylation levels were observed on OGA and the long form of OGT in
unstimulated, cortical neurons (10.8% and undetectable, respectively). The long form of
OGT also exhibited low levels of mono-glycosylation in Sf9 cells (3.3%; Fig. 2a), although
the short form of OGT showed higher levels of glycosylation (36.5% mono-glycosylated,
3.3% di-glycosylated; Fig. 1c). Five distinct glycosylation sites have been identified on OGT
by mass spectrometry29, yet OGT exists predominantly in the mono-glycosylated state in
vivo. These results highlight the complementary information obtained using the mass-
tagging approach and mass spectrometry analyses.
Quantitative studies of O-GlcNAc levels and dynamics
The ability to monitor the glycosylation levels of proteins in vivo also permits comparisons
across different tissues, organs, or disease states. Endogenous CREB exhibited similar
glycosylation levels in the adult rat hippocampus and cerebellum (44.5 ± 1.6% and 45.8 ±
2.6%, respectively; Fig. 3a) but was consistently glycosylated at lower levels in the adult rat
liver (31.7 ± 1.0%). The strong reproducibility of the measurements across multiple different
animals is striking and suggests that physiological glycosylation levels are under tight
regulatory control.
In addition to comparisons across different tissue samples, the mass-tagging approach also
facilitates studies of the dynamic cycling of O-GlcNAc. Cortical neurons were treated either
with deoxynorleucine (DON) to block UDP-GlcNAc synthesis30 or with glucosamine
(GlcN) to enhance UDP-GlcNAc synthesis30. DON decreased overall protein O-GlcNAc
levels by 0.70 ± 0.11–fold, while GlcN increased them by 2.4 ± 0.1–fold, as measured with
a general O-GlcNAc antibody (Supplementary Fig. 6). Using our mass-tagging approach,
we were able to quantify changes in glycosylation on specific proteins, including CREB and
the Golgi stacking protein GRASP55 (1.4 ± 0.1–fold and 3.1 ± 0.6–fold, respectively for
GlcN; 0.87 ± 0.05–fold and 0.86 ± 0.02–fold, respectively for DON; Fig. 3b). Notably,
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while the fold-increase in glycosylation differed considerably for CREB and GRASP55,
both proteins underwent a similar change in glycosylation stoichiometry in response to GlcN
(13.1 ± 0.2% and 10.2 ± 0.5%, respectively), consistent with the notion that UDP-GlcNAc
acts as a global modulator of OGT activity. Furthermore, we observed differences in the
rates of glycosylation for the mono- and diglycosylated forms of CREB. In response to
GlcN, the relative rate of monoglycosylation was approximately 3-fold higher than that of
diglycosylation (Fig. 3c), suggesting that once CREB becomes O-GlcNAc glycosylated, it is
less likely to be glycosylated a second time. Together, these studies underscore the power of
the mass-tagging approach to provide new insights into the kinetics of O-GlcNAc
glycosylation on specific modified subpopulations in vivo, information that would be
impossible to obtain using existing methods.
Direct interrogation of the interplay between PTMs
Establishing the presence or absence of a reciprocal ‘yin-yang’ relationship between O-
GlcNAc and O-phosphate is challenging because it typically requires knowledge of the
glycosylation sites, extensive mutagenesis, and cellular analyses31–33. Thus, we investigated
the potential for our mass-tagging strategy to provide rapid, new insights into the interplay
between O-GlcNAc and phosphorylation. Many stimuli induce phosphorylation of CREB at
Ser-133 (pS133), thereby activating CREB-dependent transcription and regulating key
processes such as glucose homeostasis, drug addiction, learning and memory34,35. To
determine whether O-GlcNAc glycosylation affects pS133 phosphorylation of CREB and
vice versa, we stimulated HEK cells with the cAMP agonist forskolin (Fsk) to induce pS133
phosphorylation or with the OGA inhibitor O-(2-acetamido-2-deoxy-D-
glucopyranosylidene)amino N-phenyl carbamate (PUGNAc) to induce CREB glycosylation.
After PEG labeling, the cell lysates were immunoblotted with a pS133-specific antibody or
total CREB antibody. This approach enabled rapid visualization of four distinct
subpopulations of CREB: (1) glycosylated, (2) nonglycosylated, (3) glycosylated and
phosphorylated, and (4) nonglycosylated and phosphorylated CREB (Fig. 4a). Simple
inspection of the blot revealed that a significant fraction of the CREB subpopulation was
simultaneously phosphorylated and glycosylated, indicating that the two modifications can
reside on the same molecule and are not mutually exclusive (i.e. not yin-yang).
Comparison of the levels of pS133 induction on the glycosylated and nonglycosylated
subpopulations revealed that forskolin stimulated CREB phosphorylation to a similar extent
in both fractions (nonglyco-CREB 1.47 ± 0.05–fold, glyco-CREB 1.55 ± 0.04–fold; Fig.
4a,b). Similarly, the level of PUGNAc-induced CREB glycosylation was unaffected by the
presence of phosphorylation at S133 (Fig. 4a,c). Thus, pS133 phosphorylation can be
stimulated independently of glycosylation and vice versa, and we observe no evidence of
interplay between the cAMP signaling pathway and OGA activity toward CREB.
We next investigated the potential for interplay between phosphorylation and glycosylation
on MeCP2. MeCP2 phosphorylation at Ser-421 and dephosphorylation at Ser-80 have been
shown to de-repress specific genes and may play an important role in coordinating activity-
dependent gene expression36,37. Using the traditional method of immunoblotting with
phospho-specific antibodies, we observed intriguing evidence for a potential yin-yang
relationship at Ser-80 on MeCP2. Specifically, increasing O-GlcNAc levels with GlcN led
to a 30.1 ± 6.9% decrease in phosphorylation at Ser-80 (pS80) in rat cortical neurons,
whereas phosphorylation at Ser-421 was unaffected (Supplementary Fig. 8a,b). To
characterize further the potential yin-yang relationship at Ser-80, we exploited our mass-
tagging strategy on neuronal lysates and immunoblotted with a pS80-specific antibody or
total MeCP2 antibody (Fig. 4d). As before, the approach resulted in rapid visualization of
four distinct post-translationally modified subpopulations. Notably, a significant fraction of
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MeCP2 was found to be simultaneously phosphorylated and glycosylated, definitively
establishing the absence of a simple yin-yang relationship.
We quantified the GlcN-induced change in glycosylation on the pS80 subpopulation relative
to the overall MeCP2 population. Surprisingly, glycosylation was induced to a greater extent
on the phosphorylated subpopulation of MeCP2 (1.42 ± 0.08–fold for pS80 MeCP2; 1.14 ±
0.06–fold for total MeCP2; Fig. 4d,e), indicative of a reverse yin-yang relationship. We also
examined the effects of GlcN on MeCP2 phosphorylation levels. Consistent with our earlier
result, GlcN induced an overall decrease in pS80 phosphorylation. However, the
glycosylated subpopulation underwent an unexpected increase in phosphorylation at Ser-80
(1.20 ± 0.06–fold), and pS80 levels decreased selectively on the nonglycosylated population
(0.71 ± 0.07–fold, Fig. 4d,f), again the opposite of a yin-yang relationship.
To examine whether this reverse yin-yang relationship occurred in response to physiological
stimuli, we induced membrane depolarization of neurons with KCl. Synchronous activation
of embryonic neurons with depolarizing amounts of KCl reduced the overall pS80 levels on
MeCP2, as reported37 (Supplementary Fig. 8c). Despite an overall decrease in global pS80
levels, membrane depolarization enhanced Ser-80 phosphorylation selectively on the
glycosylated MeCP2 subpopulation (1.56 ± 0.15– fold) and decreased Ser-80
phosphorylation only on the nonglycosylated MeCP2 subpopulation (0.90 ± 0.03–fold; Fig.
4g,h). Whereas KCl treatment induced a modest overall decrease in O-GlcNAc
glycosylation on total MeCP2 (0.89 ± 0.03–fold), the pS80 subpopulation underwent an
increase in glycosylation (1.26 ± 0.03–fold; Fig. 4g,i). Together, these results provide strong
evidence for a reverse yin-yang relationship on MeCP2.
Discussion
In this study, we demonstrate a powerful new approach for visualizing the O-GlcNAc-
glycosylated protein subpopulation in complex biological samples. Through the selective,
chemoenzymatic attachment of PEG mass tags to O-GlcNAc modification sites, in vivo
glycosylation stoichiometries can be readily quantified on endogenous proteins, without the
need for protein purification, advanced instrumentation, or expensive radiolabels. In
addition, the approach allows for direct interrogation of proteins of interest by
immunoblotting, without requiring O-GlcNAc site identification or O-GlcNAc site-specific
antibodies. This feature is critical given that glycosylation sites have been mapped for only a
small fraction of the O-GlcNAc proteome, and comprehensive analyses of all glycosylation
sites within a given protein are lacking, even for many well-studied proteins.
Our mass-tagging approach yields information that cannot be obtained using current
methods. Because glycosylation levels can be rapidly monitored by immunoblotting in
parallel, O-GlcNAc glycosylation stoichiometries can be readily profiled across the
proteome. We quantified the stoichiometries of a broad range of proteins, including proteins
that eluded detection by the O-GlcNAc antibodies RL-2 and CTD110.6. Even among
proteins with similar functions, we observed a wide range of O-GlcNAc stoichiometries in
vivo. For example, both the transcriptional repressor MeCP2 and transcription factor CREB
were mono-glycosylated at moderate levels in neurons (15.3% and 33.0%, respectively),
while the transcription factor Sp1 was 100% glycosylated at multiple sites in vivo. Similarly,
the long form of OGT exhibited very low levels of glycosylation in Sf9 cells (3.3%),
whereas the short form of OGT had a significantly higher extent of glycosylation in these
cells (39.7%). Unexpectedly, OGT was primarily mono-glycosylated despite having
multiple known glycosylation sites, which suggests a high potential for the transient
regulation of OGT activity by O-GlcNAc in response to cellular stimuli. These findings
underscore the complementarity between our mass-tagging strategy and mass spectrometry
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approaches. Although mass spectrometry provides key information about the identity and
number of O-GlcNAc sites, it cannot readily determine their relative occupancy or
interrelationship within the same molecule of protein. In contrast, our mass-tagging
approach provides a direct read-out of glycosylation stoichiometry and state (e.g., mono-,
di-, tri-, etc.), and when applied in conjunction with site-directed mutagenesis, it may reveal
O-GlcNAc stoichiometries at specific amino acid sites.
The ability to monitor glycosylation stoichiometries and states provides unique insights into
the cellular functions and regulation of O-GlcNAc glycosylation. For example, we probed
the glycosylation level of CREB across different tissues, cells and organisms in response to
a variety of perturbations. Our results revealed tissue-specific differences and tight
regulatory control over the levels of CREB glycosylation in vivo. Moreover, we found that
the glycosylation state of CREB influenced its kinetics of glycosylation: upon activation of
the hexosamine biosynthesis pathway, unglycosylated CREB was glycosylated three-times
faster than mono-glycosylated CREB, suggesting that the presence of one GlcNAc sugar on
CREB decreases the rate of deposition of another sugar. Although the presence of only one
OGT gene may suggest uniform regulation of O-GlcNAc substrates, evidence from
quantitative mass spectrometry analyses indicates that OGT regulates its substrates more
discretely29. Our approach allows this phenomenon to be explored in detail across and
within proteins of interest in response to specific stimuli. Such information would be
difficult, if not impossible, to obtain using current methods.
Elucidating the interplay of O-GlcNAc with other post-translational modifications is another
powerful application of the mass-tagging approach. For example, we demonstrated that the
mass tag enables rapid visualization of distinct post-translationally modified subpopulations,
which are distinguished by their glycosylation or phosphorylation status. As such, the
approach provides a direct read-out of whether the two modifications are mutually exclusive
on proteins of interest (i.e. yin-yang) or whether they can co-exist on the same molecule. We
found that glycosylation and phosphorylation occur independently in the case of CREB
under the stimuli tested. In addition, we discovered a surprising reverse yin-yang
relationship on MeCP2, which was undetectable by traditional methods and revealed only by
the mass-tagging approach. A yin-yang relationship on MeCP2 was observed by stimulating
O-GlcNAc levels with GlcN and monitoring phosphorylation levels on the total MeCP2
population. However, our mass-tagging strategy enabled changes in glycosylation to be
monitored specifically on the phosphorylated subpopulation and vice versa. We found that
neuronal activity or stimulation of the hexosamine biosynthesis pathway induced O-GlcNAc
glycosylation selectively on the S80-phosphorylated subpopulation of MeCP2 – the opposite
of a yin-yang relationship. One possibility is that glycosylation may mark a specific subset
of MeCP2-regulated genes and render them less susceptible to activity-dependent
derepression. Our results provide strong evidence for the close coupling of glycosylation and
phosphorylation on MeCP2 and, more broadly, we find that the net change in glycosylation
or phosphorylation on the global protein population can be the opposite of changes
occurring on specific modified subpopulations, an observation with significant implications
for studying the interplay between modifications. The complexities observed with MeCP2
underscore the importance of carefully dissecting the intricate interplay between post-
translational modifications on a molecular level and of developing new methods to address
these questions.
In conclusion, we have developed a new mass-tagging strategy to advance our
understanding of the stoichiometry, complex regulation, and cellular dynamics of O-
GlcNAc glycosylation. In the future, we anticipate extending this approach to explore the
complex ‘codes’ or networks of post-translational modifications on O-GlcNAc-modified
proteins through the use of antibodies against other modifications. Moreover, we envision
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that this general strategy of tagging modifications with resolvable PEG mass tags will prove
valuable for the study of other post-translational modifications and poorly understood
glycosylation motifs.
METHODS
General procedure for chemoenzymatic labeling with mass tags
Protein lysates (100 μg at 3.3 μg μl−1 in 1% SDS) were diluted 5-fold to a final buffer
concentration of 10 mM HEPES pH 7.9, 10 mM MgCl2, 100 mM NaCl and 1.8% Triton-
X100, and 0.2% SDS. The lysates (100 μg at 0.67 μg μl−1) were incubated with Y289L
GalT23 (7 μg; 0.1 mg ml−1 final concentration) and UDP-ketogalactose derivative 1 (500
μM) for 16 h at 4 °C. The samples were then diluted to 200 μl and precipitated by sequential
mixing with 600 μl of MeOH, 200 μl of CHCl3, and 450 μl H2O, followed by
centrifugation at 23,000 ×g for 15 min. Precipitated protein was washed with 450 μl of
MeOH and centrifuged at 23,000 ×g for 10 min. After allowing the protein pellet to dry, the
pellet was resuspended in labeling buffer (43.6 μl at 2.3 μg μl−1; 7 M urea, 10 mM HEPES
pH 7.9, 2% CHAPS, 1 mM DTT, Complete™ protease inhibitor cocktail (Roche) and 1 mM
PMSF). The samples were then acidified to pH 4.5 by the addition of 1.4 μl of 1.8 M
NaOAc (final concentration 50 mM) and incubated with 6 mM aminooxy-functionalized
PEG (2 or 3; 5 μl of a 60 mM aqueous stock) for 20–24 h at RT. To stop the reaction, the
samples were neutralized with 1M HEPES pH 7.9 (2 μl), precipitated using the MeOH/
CHCl3/H2O method described above, and re-suspended in 1% SDS. The UDP-ketogalactose
derivative 1 was omitted as a control in each case. If desired, complex N-glycans can be
removed prior to (or during) labeling using PNGaseF as previously reported25,38.
Membrane-associated glycoproteins can be removed readily by subcellular fractionation (see
Supplementary Methods). However, such procedures are not necessary as the O-GlcNAc
proteins of interest are selectively visualized by immunoblotting.
Quantification of O-GlcNAc stoichiometries
The following samples were used to detect glycosylation of the indicated proteins in Fig. 1c:
293T whole cell lysate (Sp1), rat hypothalamus crude nuclear pellet (MeCP2), rat brain
detergent-soluble fraction (synapsin IIa, Nup62), whole cell lysate from cultured embryonic
neurons (CREB), cytosolic fraction from PUGNAc-treated cultured embryonic neurons
(OGA), and p75-OGT purified from Sf9 cells. For Fig. 3a, the liver, hippocampus or
cerebral cortex was harvested from adult Sprague Dawley rats, and crude nuclear pellets
were processed. Animal protocols were approved by the Institutional Animal Care and Use
Committee at Caltech, and the procedures were performed in accordance with the Public
Health Service Policy on Humane Care and Use of Laboratory Animals. Cell lysates were
prepared as described in the Supplementary Methods. Each sample and its corresponding
negative control (lacking ketogalactose probe 1 incorporation) was subjected to
chemoenzymatic labeling with PEG mass tags, resolved on 4–12% Bis-Tris NuPAGE gels
(Invitrogen), and transferred to nitrocellulose or PVDF membranes. The membranes were
immunoblotted with antibodies against each protein of interest (see Supplementary
Methods). After incubation with secondary antibodies (IRDye 800 goat anti-rabbit or Alexa
Fluor 680 goat anti-mouse), proteins were visualized and quantified using an Odyssey
infrared imaging system (LI-COR Biosciences). To quantify O-GlcNAc stoichiometries, the
intensities of the PEG-shifted band (glycosylated protein fraction) and the unshifted band
(non-glycosylated protein fraction) were measured using Odyssey imaging software
(Version 2.1). The resulting values of the PEG-shifted bands were corrected for non-specific
background by subtracting the background intensity from negative control reactions. For
data and statistical analyses, mean values, standard error of the mean, and P-values (paired,
two-tailed, Student’s T-tests, α-value = 0.05) were calculated using the program Excel.
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Monitoring O-GlcNAc dynamics
Rat cortical neurons were treated with DON (5 μM, 6 h), GlcN (10 mM, 6 h) or vehicle (2
mM HEPES pH 7.5) and harvested by rapid lysis in boiling 1% SDS containing Complete ™
protease inhibitor cocktail and 1 mM PMSF. Lysates were sonicated, centrifuged, and
measured for protein concentration using the BCA assay. Each sample (100 μg) was
subjected to chemoenzymatic labeling with the PEG derivatives 2 or 3. Following resolution
by SDS-PAGE and gel transfer, the membranes were blotted sequentially with anti-CREB
and anti-GRASP55 antibodies. Glycosylation stoichiometries were calculated using both
PEG derivatives.
Studying the interplay between phosphorylation and glycosylation
For CREB, HEK 293T cells were treated with Fsk (10 μM, 25 min), PUGNAc (100 μM, 6
h), or vehicle only (DMSO for Fsk, water for PUGNAc). Following treatment, cells were
harvested by rapid lysis in boiling 1% SDS containing Complete™ protease inhibitor
cocktail, 1 mM PMSF, 50 mM NaF and 1 mM Na3VO4, and the lysates were sonicated,
centrifuged, and measured for protein concentration. The lysates (100 μg) were then
subjected to chemoenzymatic labeling as described above, resolved by SDS-PAGE (30 μg),
and immunoblotted in parallel for pS133 and total CREB. pS133 CREB levels and
glycosylation stoichiometries were calculated. The pS133 signals were corrected for total
CREB levels in each fraction and then normalized with respect to the basal pS133
phosphorylation level in each case.
To assess the interplay between MeCP2 phosphorylation at Ser-80 (pS80) or Ser-421
(pS421) and glycosylation, embryonic day 18 cortical neurons were incubated after 4 days
in vitro in the presence or absence of GlcN (10 mM, 6 h). pS421 levels were induced by
neuronal depolarization (55 mM KCl, 2 h). pS421-phosphorylated MeCP2 was detected
from whole cell lysate as the slower migrating MeCP2 band upon 8% SDS-PAGE and
MeCP2 immunoblotting36,37. pS80 levels were assessed by parallel immunoblotting of
nuclear extracts with pS80-specific and total MeCP2 antibodies.
For glycosylation assays of pS80 and total MeCP2, nuclear lysates of neuronal samples were
subjected to chemoenzymatic labeling with PEG derivative 3 as described above, resolved in
parallel on 4–12% Bis-Tris NuPAGE gels, and immunoblotted with either a pS80-specific or
total MeCP2 antibody. To quantify pS80 levels, the pS80 signal was corrected for the total
MeCP2 signal in each fraction. pS80 levels were plotted relative to the levels of basal
nonglycosylated MeCP2. Glycosylation stoichiometries of pS80 and total MeCP2 were
calculated as described above.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Mass-tagging strategy for quantifying O-GlcNAc glycosylation levels on specific proteins.
(a) Schematic of the approach. O-GlcNAc-modified proteins are chemoenzymatically
labeled using the UDP-ketogalactose analogue 1 and an engineered GalT enzyme, followed
by reaction with an aminooxy-functionalized PEG mass tag (2 or 3). This approach enables
facile visualization of O-GlcNAc-glycosylated species upon SDS-PAGE and
immunoblotting with antibodies against proteins of interest. (b) Validation of the approach
using CREBmono and CREBco. CREBmono was 28.2% glycosylated and existed primarily in
the mono-glycosylated state, whereas CREBco was 88.8% glycosylated and present in
multiply glycosylated forms. (c) In vivo O-GlcNAc stoichiometries vary significantly even
among proteins with similar functions. Cell lysates (100 μg) from 293T cells (source of
Sp1), adult rat brain (source of MeCP2, Nup62, and synapsin Ia (upper band) and IIa (lower
band)), embryonic neuronal cultures (source of CREB, and OGA) or purified p75-OGT
(0.43 μg) from Sf9 cells were subjected to chemoenzymatic labeling, SDS-PAGE, and
immunoblotting with antibodies against the indicated proteins. See Methods for details. In
all cases, 1 was excluded as a control for selectivity. The indicated glycosylation
stoichiometries were determined by measuring the relative intensities of the glycosylated
and nonglycosylated bands. (….) denotes the nonglycosylated protein fraction, (→) denotes
O-GlcNAc glycosylated protein fraction shifted with 2 or 3. Full-length blots are presented
in Supplementary Figure 9.
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Figure 2.
Validation of the approach. (a) Distinct antibodies detect the same glycosylation
stoichiometry on OGT (AL-28 and DM-17), CREB (Chemicon 5432 and Upstate 06-863),
and MeCP2 (Hu and Upstate 07-013). p110-OGT was expressed in Sf9 cells, endogenous
CREB was from rat liver, and MeCP2 was co-expressed with OGT in Sf9 cells. (b) As little
as 0.8% of glycosylated OGT is readily detected. Sf9 cell lysate containing over-expressed
p110-OGT was chemoezymatically labeled with PEG derivative 3 and diluted with
unlabeled lysate to generate standards with varying percentages of label incorporation. The
lysate was resolved by SDS-PAGE and immunoblotted with the anti-OGT antibody DM-17.
The limit of detection was defined as the lowest stoichiometry value within 10% of the
linear fit. See Supplementary Methods for details. (c) Detection of PEG incorporation into
ketogalactose-labeled Nup62 is linear across a wide range of stoichiometries (0–100%).
293T cell lysate was labeled with UDP-ketogalactose 1 and then diluted with varying
amounts of unlabeled lysate to simulate different levels of glycosylation. Each mixture was
reacted with 2, resolved by SDS-PAGE, and immunoblotted for Nup62. Full-length blots are
presented in Supplementary Figure 9.
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Figure 3.
Monitoring O-GlcNAc glycosylation levels on proteins across various tissues and after
cellular stimulation. (a) CREB is O-GlcNAc glycosylated at higher levels in the rat
cerebellum (CE) and hippocampus (HP) than in the liver (LV). Cell lysates from the
indicated tissues were chemoenzymatically labeled, resolved by SDS-PAGE, and
immunoblotted for CREB. A representative immunoblot from one animal is shown. Plotted
are the glycosylation stoichiometries of CREB averaged across multiple animals (n = 4–6). *
P = 0.0003, ** P = 0.03. (b) O-GlcNAc glycosylation levels of CREB and GRASP55
decreased in rat embryonic neuronal cultures upon DON treatment (D) and increased upon
GlcN treatment (G) relative to untreated neurons (U). Cell lysates were chemoenzymatically
labeled, resolved by SDS-PAGE, and immunoblotted for the indicated proteins. A
representative immunoblot is shown. Plotted are the glycosylation stoichiometries averaged
across n = 3 experiments. * P = 0.002, ** P = 0.006, *** P = 0.001. (c) The rate constant for
monoglycosylation of CREB is approximately threefold higher than that for diglycosylation
of CREB. Neuro2a cells were treated with 10 mM GlcN for the indicated times. Crude
nuclear protein lysates were chemoezymatically labeled, resolved by SDS-PAGE, and
immunoblotted for CREB. Formation of monoglycosylated or diglycosylated CREB was
plotted as a function of time for n = 3 experiments. See Supplementary Methods for details.
Data represent mean ± s.e.m. Statistical analyses were performed using the Student’s t-test
(two-tailed, paired). Full-length blots are presented in Supplementary Figure 9.
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Figure 4.
Dissecting the interplay between O-GlcNAc and phosphorylation. Detection of four
subpopulations of CREB or MeCP2: glycosylated (1), nonglycosylated (2), glycosylated and
phosphorylated (3), and nonglycosylated and phosphorylated (4). (a) CREB can be
simultaneously glycosylated and phosphorylated. Mass-tagged lysates from 293T cells
treated with Fsk, PUGNAc or vehicle were immunoblotted with a pS133-specific or general
CREB antibody. (b) Fsk stimulates pS133 phosphorylation of glycosylated and non-
glycosylated CREB similarly (n = 6). (c) Inhibition of OGA increases CREB glycosylation
levels on phosphorylated and total CREB similarly (n = 4). Neither Fsk nor PUGNAc
affected overall CREB glycosylation or pS133 phosphorylation levels, respectively
(Supplementary Fig. 7). (d) Complex interplay between MeCP2 glycosylation and
phosphorylation. Mass-tagged lysates from neurons treated with GlcN or vehicle were
immunoblotted with a pS80-specific or general MeCP2 antibody (n = 6). (e) GlcN increases
MeCP2 glycosylation levels predominantly on the pS80 subpopulation. (f) GlcN decreases
pS80 levels on the nonglycosylated subpopulation and increases pS80 levels on the
glycosylated subpopulation. (g) Reverse yin-yang relationship on MeCP2 under
physiological conditions. Mass-tagged nuclear extracts from synchronously depolarized or
non-depolarized neurons were immunoblotted with a pS80-specific or general MeCP2
antibody (n = 8). (h) Neuronal depolarization induces pS80 levels on glycosylated MeCP2.
(i) Depolarization increases the glycosylation level of pS80 MeCP2, while decreasing that of
total MeCP2. UDP ketogalactose 1 was excluded as a control. Data represent mean ± s.e.m.
Statistics were analyzed by Student’s t-test. * P = 0.0005, ** P = 0.00007 for (b). * P = 0.02,
** P = 0.0007 for (c). * P = 0.04, ** P = 0.008 for (e). * P = 0.01, ** P = 0.04 for (f). * P =
0.01, ** P = 0.001 for (h). * P = 0.04, ** P = 0.001 for (i). Full-length blots are presented in
Supplementary Figure 9.
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